BIOFIRE® Respiratory 2.1 plus (RP2.1plus) Panel

The new BIOFIRE® Respiratory 2.1 plus Panel enables rapid and accurate automated detection of pathogens behind respiratory infections. It tests for 19 viruses including SARS-CoV-2, and 4 bacteria that cause respiratory tract infections in 45 min.

  • Simple: 2 minutes of hands-on time
  • Fast: Turnaround time of 45 minutes for RP2.1 plus
  • Comprehensive: 23 targets including viruses and bacteria
  • Accurate: Overall 97.1% sensitivity and 99.3% specificity (prospective specimens) *1 SARS-CoV-2 98.4% PPA and 98.9% NPA*2


1: Based on the prospective portion of the clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel
2: Overall performance based on prospective SARS-COV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, Data on file, BIOFIRE Diagnostics.


Add to your selection

Do you need more information?

Simple, comprehensive respiratory testing

1 Test.  23 Targets. ~45 Minutes.

The BIOFIRE RP2.1 plus Panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. Fast and comprehensive, the BioFire RP2.1 Panel offers a run time of about 45 minutes, enabling high efficiency and throughput on the BIOFIRE® FILMARRAY® 2.0 and the BIOFIRE® FILMARRAY® Torch Systems. Rapid respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.

  • Simple: 2 minutes of hands-on time
  • Easy: No precise measuring or pipetting required
  • Fast: Turnaround time of about 45 minutes
  • Comprehensive: 23 target respiratory panel


BIOFIRE® Respiratory 2.1 plus Panel is one of six FDA-cleared and/or CE-marked panels for use on the BIOFIRE® FILMARRAY® multiplex PCR system. Taken together, the six BIOFIRE® panels comprise the largest infectious disease pathogen menu commercially available. The other available panels are:

The BIOFIRE RP 2.1 plus Panel Menu

Viruses Bacteria

Adenovirus Coronavirus 229E

Coronavirus HKU1

Coronavirus NL63

Coronavirus OC43

Middle East respiratory syndrome coronavirus (MERS-CoV)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Human metapneumovirus

Human rhinovirus/enterovirus

Influenza A virus

Influenza A virus A/H1

Influenza A virus A/H3

Influenza A virus A/H1-2009

Influenza B virus

Parainfluenza virus 1

Parainfluenza virus 2

Parainfluenza virus 3

Parainfluenza virus 4

Respiratory syncytial virus

Bordetella parapertussis

Bordetella pertussis

Chlamydia pneumoniae

Mycoplasma pneumoniae

Improve Clinical Outcomes

The BIOFIRE® FILMARRAY® Respiratory Panels have has been shown to significantly reduce ICU days3 and duration of antibiotic use.Optimize patient management with clinically actionable results.


3. Martinez R, et al. Clinical Virology Symposium, Poster #C-368, May 2016.

4. Rogers B, et al. Arch. Path. & Lab. Med. 2015;139(5): 636-41.

Panel Specification

Sample Handling Performance Parameters
Sample Type: Nasopharyngeal Swab Hands-on time: Approx. 2 minutes
Sample Volume: 300 μL Run turnaround time: ~45 minutes


Clinical Outcomes PUBLICATIONS



Economic Outcomes PUBLICATIONS








Fast facts on Respiratory Pathogens

What are Respiratory Pathogens?

The vast majority of respiratory illnesses are caused by viruses and bacteria. In both children and adults, acute respiratory infections  (ARI) are most frequently due to infections with Influenza A and B viruses, Parainfluenza viruses 1, 2 and 3, Respiratory Syncytial Virus (RSV A and B), Adenoviruses and Rhinoviruses. Others pathogens such as Coronaviruses, Bocaviruses, Enteroviruses, Parainfluenza 4, Human Metapneumovirus, Mycoplasma pneumonia and Chlamydophila pneumoniae also infect  the respiratory tract and can cause various diseases from mild self-limiting upper respiratory infections to potentially threatening pneumonia.

Who is most at risk?

Anyone can become infected and ill with these respiratory pathogens. However, young children, the elderly, immunocompromised or weakened individuals (including those with chronic disease, cancer, or in intensive care) are most likely to suffer serious and potentially life-threatening pneumopathies.

What are the benefits of Respiratory pathogens molecular testing?

Clinical symptoms for different respiratory illnesses are similar so in vitro diagnostic molecular methods are necessary to determine the causative agents. Early, rapid and specific detection of the virus or bacteria involved using real-time PCR methods is essential to provide patient-tailored therapy for better outcomes. An accurate diagnosis may also help to control outbreaks, reduce potential antibiotic resistance and facilitate a more rapid patient recovery.


Technical Notes and Advisory Notes:

Instructions for Use and Manuals:

Product Support Documents:

EC Declarations of conformity:

Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics